| Allogeneic or Haploidentical Stem Cell Transplant Followed By High-Dose Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (NCT02057770) | Washington University School of Medicine | 2014-02-28 |
| Volasertib + Decitabine in Patients With Acute Myeloid Leukemia (AML) (NCT02003573) | Boehringer Ingelheim | 2014-01-29 |
| Connect® Myeloid Disease Registry (NCT01688011) | Celgene | 2013-12-12 |
| Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS). (NCT01835587) | Celgene | 2013-10-25 |
| Efficacy of Oral Azacitidine Plus Best Supportive Care as Maintenance Therapy in Subjects With Acute Myeloid Leukemia (AML) in Complete Remission (NCT01757535) | Celgene | 2013-04-24 |
| Azacitidine in Patients Undergoing Matched Unrelated Stem Cell Transplantation (NCT01747499) | Washington University School of Medicine | 2013-04-15 |
| Genomic Predictors of Decitabine Response in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes (NCT01687400) | Washington University School of Medicine | 2013-02-12 |
| Volasertib in Combination With Low-dose Cytarabine in Patients Aged 65 Years and Above With Previously Untreated Acute Myeloid Leukaemia, Who Are Ineligible for Intensive Remission Induction Therapy (POLO-AML-2) (NCT01721876) | Boehringer Ingelheim | 2013-01-29 |
| CPX-351 Salvage Therapy Followed by Haplo-Cord Transplant for Relapsed/Refractory Leukemia or Myelodysplastic Syndrome (NCT03393611) | Weill Medical College of Cornell University | 2012-11-30 |
| BI 836858 Dose Escalation in Patients With Refractory or Relapsed Acute Myeloid Leukemia and in Patients With AML in Complete Remission With High Risk to Relapse (NCT01690624) | Boehringer Ingelheim | 2012-09-13 |
| Randomised Study of Azacitidine Versus Azacitidine With Vorinostat in Patients With AML or High Risk MDS (NCT01617226) | University of Birmingham | 2012-09-01 |
| Volasertib in Japanese Patients With Acute Myeloid Leukemia (AML) (NCT01662505) | Boehringer Ingelheim | 2012-08-01 |
| A Study of CSL362 in Patients With CD123+ Acute Myeloid Leukemia Currently in Remission (NCT01632852) | CSL Limited | 2012-07-01 |
| An Observational Post Authorisation Study to Evaluate Safety and Efficacy in Patients Receiving Azacitidine in Daily Clinical Practice in the Netherlands (NCT02891551) | Celgene | 2012-05-01 |
| Validation of a Comprehensive Health Status Assessment Scale in Elderly Patients (≥ 65 Years) With Hematological Malignancies (NCT02164071) | Celgene | 2012-04-11 |
| Open Label Study to Evaluate Safety and Efficacy of 2 Doses of Quizartinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia (NCT01565668) | Daiichi Sankyo | 2012-04-01 |
| Azacitidine After Chemotherapy and Donor Lymphocyte Infusion in Patients With Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome Previously Treated With Donor Stem Cell Transplant (NCT01390311) | Washington University School of Medicine | 2012-04-01 |
| A Study of AC220 Given After Transplant in Subjects With Acute Myeloid Leukemia (AML) (NCT01468467) | Daiichi Sankyo | 2012-04-01 |
| Study to Evaluate Pharmacokinetics, Food Effect, Safety and Efficacy of Oral Azacitidine (NCT01519011) | Celgene | 2012-02-07 |
| Risk-adapted Therapy for Primary Acute Myeloid Leukemia (NCT04687098) | Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias | 2012-02-01 |
| Safety and Efficacy Study of Idarubicin Dose Intensification to Treat Acute Myeloid Leukemia (NCT01518556) | Konkuk University Medical Center | 2011-07-01 |
| Plerixafor and Sargramostim (GM-CSF) for Mobilization of Allogeneic Sibling Donors (NCT01158118) | Washington University School of Medicine | 2011-04-01 |
| A Study to Analyze the Occurrence of Transformation From Myelodysplastic Syndrome to Acute Myeloid Leukemia in Patients With Myelodysplastic Syndrome Who Received Revlimid® 5 mg Capsules and Who Are Continuing or no Longer Continuing Revlimid Treatment (NCT02921815) | Celgene | 2011-03-03 |
| Use of Saline-Washed Platelet and Red Cell Transfusions in Adult Acute Leukemia (NCT01976442) | University of Rochester | 2011-03-01 |
| Haematopoietic Stem Cell Transplantation (HSCT) in Comparison to Conventional Consolidation Therapy for Patients With Acute Myeloid Leukemia (AML) (Intermediate Risk) </= 60y. After First CR (NCT01246752) | University Hospital Carl Gustav Carus | 2011-02-10 |
| Chemosensitization With Plerixafor Plus G-CSF in Acute Myeloid Leukemia (NCT00906945) | Washington University School of Medicine | 2011-02-01 |
| Cladribine Based Induction Therapy With All-Trans Retinoic Acid and Midostaurin in Relapsed/Refractory AML (NCT01161550) | Washington University School of Medicine | 2010-11-01 |
| Pharmacokinetics of Anidulafungin (Ecalta ®) Intravenous Given to Patients at High Risk for Developing Invasive Fungal Disease (NCT01249820) | Radboud University Medical Center | 2010-11-01 |
| MSC and HSC Coinfusion in Mismatched Minitransplants (NCT01045382) | University of Liege | 2010-07-01 |
| Intravenous (IV) Decitabine and Oral Bexarotene for Acute Myelogenous Leukemia (AML) (NCT01001143) | Washington University School of Medicine | 2010-05-01 |
| IV Plerixafor With Mitoxantrone Etoposide and Cytarabine for Acute Myeloid Leukemia (AML) (NCT01027923) | Washington University School of Medicine | 2010-05-01 |
| Azacitidine and Lenalidomide for Acute Myeloid Leukemia (NCT01016600) | Washington University School of Medicine | 2010-04-01 |
| Decitabine Maintenance for Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS) Post Transplant (NCT00986804) | Washington University School of Medicine | 2009-12-01 |
| Trial of Pimasertib in Hematological Malignancies (NCT00957580) | EMD Serono | 2009-09-30 |
| Pilot Study of Unrelated Cord Blood Transplantation (NCT00916045) | King's College Hospital NHS Trust | 2009-09-01 |
| Combination of Sorafenib and Vorinostat in Poor-risk Acute Myelogenous Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS) (NCT00875745) | Indiana University | 2009-04-01 |
| Sitagliptin Umbilical Cord Blood Transplant Study (NCT00862719) | Indiana University | 2009-03-01 |
| Mismatched Donor Lymphocyte Infusions for Relapsed Disease Following Allogeneic Stem Cell Transplantation (NCT00859586) | National Heart, Lung, and Blood Institute (NHLBI) | 2009-02-01 |
| Oral Clofarabine for Acute Myeloid Leukemia (NCT00727766) | Washington University School of Medicine | 2009-01-01 |
| SCH 727965 in Patients With Acute Myelogenous Leukemia and Acute Lymphoblastic Leukemia (P04717AM2)(TERMINATED) (NCT00798213) | Merck Sharp & Dohme LLC | 2009-01-01 |
| Evaluating the Safety and Effectiveness of an Umbilical Cord Blood Stem Cell Transplant (BMT CTN 0604) (NCT00864227) | Medical College of Wisconsin | 2008-12-01 |
| Phase I/IIa Trial to Investigate BI 6727 (Volasertib) as Monotherapy or in Combination With Cytarabine in Acute Myeloid Leukaemia (NCT00804856) | Boehringer Ingelheim | 2008-11-27 |
| Bone Marrow Transplant From Partially Matched Donors and Nonmyeloablative Conditioning for Blood Cancers (BMT CTN 0603) (NCT00849147) | Medical College of Wisconsin | 2008-10-01 |
| Pilot Study of Expanded, Donor Natural Killer Cell Infusions for Refractory Non-B Lineage Hematologic Malignancies and Solid Tumors (NCT00640796) | St. Jude Children's Research Hospital | 2008-09-01 |
| LBH589 Plus Decitabine for Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML) (NCT00691938) | Washington University School of Medicine | 2008-06-01 |
| Lentivirus Transduced Acute Myeloid Leukaemia Blasts Expressing B7.1 (CD80) and IL-2 (NCT00718250) | King's College Hospital NHS Trust | 2008-05-01 |
| BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment (NCT00632749) | Boehringer Ingelheim | 2008-05-01 |
| Treatment of Non Promyelocytic Acute Myeloid Leukaemia on Elderly Patients by Low Dose Cytosar Plus Arsenic Trioxide (NCT00850304) | Tehran University of Medical Sciences | 2007-10-01 |
| A Phase I Trial of Alloreactive Cell Infusion Following Transplantation of Haplotype Cells in Patients With Myeloid Malignancies (NCT00569179) | Indiana University | 2007-08-01 |
| AMD3100 Plus Mitoxantrone, Etoposide and Cytarabine in Acute Myeloid Leukemia (NCT00512252) | Washington University School of Medicine | 2007-07-01 |
| Pilot Study of Reduced Intensity Haematopoietic Stem Cell Transplantation in Patients With Poor Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukaemia (AML) Utilising Conditioning With Fludarabine, Busulphan and Thymoglobulin (NCT00915811) | King's College Hospital NHS Trust | 2007-06-01 |
| Lenalidomide in Older Patients With Acute Myeloid Leukemia Without Chromosome 5q Abnormalities (NCT00546897) | Washington University School of Medicine | 2007-02-01 |
| BI 2536 Infusional Treatment in Patients Over 60 Years of Age With Refractory or Relapsed Acute Myeloid Leukaemia (NCT00701766) | Boehringer Ingelheim | 2006-10-01 |
| Feasibility of Haploidentical Hematopoietic Stem Cell Transplantation Using CAMPATH-1H (NCT00458250) | Tehran University of Medical Sciences | 2006-09-01 |
| Randomised Prospective Comparison of the NMA Allograft and the Traditional Allograft in Acute Myeloid Leukaemia (NCT00224614) | Assistance Publique - Hôpitaux de Paris | 2005-07-01 |
| Study for Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) (NCT00129948) | SGX Pharmaceuticals, Inc. | 2005-07-01 |
| Gemtuzumab Ozogamicin in Combination With A-HAM in Refractory AML (GO-A-HAM) (NCT00143975) | University of Ulm | 2004-06-01 |
| Study Evaluating AMD3100 for Transplantation of Sibling Donor Stem Cells in Patients With Hematological Malignancies (NCT00241358) | Washington University School of Medicine | 2004-05-01 |
| Registry of Myelodysplastic Syndromes and Therapy-related Acute Myeloid Leukemia (NCT06956755) | Groupe Francophone des Myelodysplasies | 2003-07-07 |